Literature DB >> 35925379

Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing Hepatic 90Yttrium Radioembolization Therapy.

Cassidy R Dodson1, Colin Marshall1,2, Jared C Durieux2, Patrick F Wojtylak2, Jon C Davidson1,2, Raymond F Muzic1,2, Arash Kardan3.   

Abstract

RATIONALE: Currently, the estimated absorbed radiation dose to the lung in 90Y radioembolization therapy is calculated using an assumed 1 kg lung mass for all patients. The aim of this study was to evaluate whether using a patient-specific lung mass measurement for each patient rather than a generic, assumed 1 kg lung mass would change the estimated lung absorbed dose.
METHODS: A retrospective analysis was performed on 68 patients who had undergone 90Y radioembolization therapy at our institution. Individualized lung volumes were measured manually on CT scans for each patient, and these volumes were used to calculate personalized lung masses. The personalized lung masses were used to recalculate the estimated lung absorbed dose from the 90Y therapy, and this dose was compared to the estimated lung absorbed dose calculated using an assumed 1 kg lung mass.
RESULTS: Patient-specific lung masses were significantly different from the generic 1 kg when compared individually for each patient (p < 0.0001). Median individualized lung mass was 0.71 (IQR: 0.59, 1.02) kg overall and was significantly different from the generic 1 kg lung mass for female patients [0.59 (0.50, 0.68) kg, (p < 0.0001)] but not for male patients [0.99 (0.71, 1.14) kg, (p = 0.24)]. Median estimated lung absorbed dose was 4.48 (2.38, 11.71) Gy using a patient-specific lung mass and 3.45 (1.81, 6.68) Gy when assuming a 1 kg lung mass for all patients. The estimated lung absorbed dose was significantly different using a patient-specific versus generic 1 kg lung mass when comparing the doses individually for each patient (p < 0.0001). The difference in the estimated lung absorbed dose between the patient-specific and generic 1 kg lung mass method was significant for female patients as a subgroup but not for male patients.
CONCLUSIONS: The current method of assuming a 1 kg lung mass for all patients inaccurately estimates the lung absorbed dose in 90Y radioembolization therapy. Using patient-specific lung masses resulted in estimated lung absorbed doses that were significantly different from those calculated using an assumed 1 kg lung mass for all patients. A personalized dosimetry method that includes individualized lung masses is necessary and can warrant a 90Y dose reduction in some patients with lung masses smaller than 1 kg. LEVEL OF EVIDENCE: Level 3, Retrospective Study.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Entities:  

Keywords:  90Y radioembolization; Lung absorbed dose; Personalized dosimetry

Year:  2022        PMID: 35925379     DOI: 10.1007/s00270-022-03197-w

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.797


  15 in total

Review 1.  Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.

Authors:  Chadwick L Wright; Jeff D Werner; Jerry M Tran; Vanessa L Gates; Ali A Rikabi; Manisha H Shah; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2012-05       Impact factor: 3.464

2.  Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.

Authors:  Etienne Garin; Lambros Tselikas; Boris Guiu; Julia Chalaye; Julien Edeline; Thierry de Baere; Eric Assenat; Vania Tacher; Corentin Robert; Marie Terroir-Cassou-Mounat; Denis Mariano-Goulart; Giuliana Amaddeo; Xavier Palard; Antoine Hollebecque; Marilyne Kafrouni; Hélène Regnault; Karim Boudjema; Serena Grimaldi; Marjolaine Fourcade; Hicham Kobeiter; Eric Vibert; Samuel Le Sourd; Lauranne Piron; Danièle Sommacale; Sophie Laffont; Boris Campillo-Gimenez; Yan Rolland
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-06

3.  Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.

Authors:  Neena A Davisson; Zachary L Bercu; Sarah C Friend; Elisavet Paplomata; Robert M Ermentrout; Janice Newsome; Bill S Majdalany; Nima Kokabi
Journal:  J Vasc Interv Radiol       Date:  2020-04-16       Impact factor: 3.464

4.  Safety of Radioembolization with (90)Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels.

Authors:  P M Paprottka; K J Paprottka; A Walter; A R Haug; C G Trumm; S Lehner; W P Fendler; T F Jakobs; M F Reiser; C J Zech
Journal:  Cardiovasc Intervent Radiol       Date:  2015-05-20       Impact factor: 2.740

5.  Calculation of lung mean dose and quantification of error for 90 Y-microsphere radioembolization using 99m Tc-MAA SPECT/CT and diagnostic chest CT.

Authors:  Benjamin Lopez; Armeen Mahvash; Marnix G E H Lam; S Cheenu Kappadath
Journal:  Med Phys       Date:  2019-06-11       Impact factor: 4.071

6.  Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity.

Authors:  A J A T Braat; S C Kappadath; H Ahmadzadehfar; C L Stothers; A Frilling; C M Deroose; P Flamen; D B Brown; D Y Sze; A Mahvash; M G E H Lam
Journal:  Cardiovasc Intervent Radiol       Date:  2019-01-02       Impact factor: 2.740

7.  A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors.

Authors:  Helmut Dittmann; Daniel Kopp; Juergen Kupferschlaeger; Diana Feil; Gerd Groezinger; Roland Syha; Matthias Weissinger; Christian la Fougère
Journal:  J Nucl Med       Date:  2018-01-25       Impact factor: 10.057

8.  Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?

Authors:  Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2020-10-01       Impact factor: 2.740

9.  Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.

Authors:  Shoaib Rafi; Sarat M Piduru; Bassel El-Rayes; John S Kauh; David A Kooby; Juan M Sarmiento; Hyun S Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2012-09-07       Impact factor: 2.740

Review 10.  Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.

Authors:  Bruno Sangro; Diego Martínez-Urbistondo; Lourens Bester; Jose I Bilbao; Douglas M Coldwell; Patrick Flamen; Andrew Kennedy; Jens Ricke; Ricky A Sharma
Journal:  Hepatology       Date:  2017-07-27       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.